Key Drivers
- Cash Flow Strength
- Margin Compression
- Leverage Rising
AIAI Summary
PBH is now better viewed as a revenue-quality and margin-discipline story than a pure growth name: the record quarter shows strong underlying earnings power, but the guidance cut, delayed launches and softer food-service demand mean investors need proof that the slowdown is timing-related rather than a more persistent demand issue before paying for a rerating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Flow Strength
- •Margin Compression
- •Leverage Rising
PBH remains profitable and cash-generative, but softer quarterly margins, higher leverage, and a highly intangible-heavy balance sheet make the stock look less compelling at current valuation.
Price Behavior
Key Price Behavior Insights:
- •Trend still higher
- •$50 support holds
- •Breakout needs follow-through
PBH has trended modestly higher over the last month and remains constructive above $50, but its failed push to $54.85 and nearby resistance at $54.4–$54.9 mean it needs a fresh breakout to extend upside.
Brief spike to $54.85 was not sustained, then price eased back to $51.38
Sentiment & News
Key News Insights:
- •Earnings beat
- •Guidance raised
- •Institutional buying
Prestige Consumer Healthcare delivered a better-than-expected quarter with revenue and EPS beats, raised full-year guidance on acquisition contributions, and saw mostly supportive institutional buying, while Premium Brands' outlook change appears tied more to timing and restructuring than to weaker demand.
The headlines are modestly positive for PBH, pointing to improving execution and near-term support, though some of the outlook lift is still driven by acquisitions and timing effects
Similar Companies in Healthcare
Other companies in the same sector with AI ratings